Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. Companies
  3. Medical / Health Care
  4. Medical Monitoring
  5. RTI Group AB

LTS -Transdermal Therapeutic Systems for Improved Outcomes

SHARE
LTS Lohmann Therapie-Systeme AG specializes in transdermal therapeutic systems (TTS) that enhance patient outcomes by ensuring controlled and balanced drug release, reducing peak concentrations, and mitigating common side effects such as nausea and vomiting. These systems provide a non-invasive delivery route, suitable for active substances with low oral bioavailability, ensuring improved efficacy and conservation of expensive materials. The TTS innovations accommodate individual market positioning and lifecycle management of established products. They are well-suited for patients with special needs, including those with Parkinson’s disease, and are particularly beneficial for children, older adults, and patients with complex care requirements due to easier application and reduced dosage intervals. Moreover, these systems can support enhanced patient compliance by minimizing interruptions, especially with multi-day patches, even for patients facing difficulty swallowing conventional oral dosages.
Most popular related searches
drug release
oral bioavailability
transdermal
therapy system
Parkinson`s disease
patient care
metabolism improve
pharmaceutical application
drug concentration
patient support

TTS that actively improve outcomes for all
Transdermal therapeutic systems (TTS) can be applied effectively and discreetly by the patient with the active substance entering the bloodstream transdermally. As the number of active substances suitable for transdermal delivery grows, we are leading the way in creating technologies that support that growth.

  • Improved compliance through convenient application and less side effects.

  • Easier for children, older people and patients requiring complex care.

  • Ideal for patients who have difficulty swallowing.

  • Less interuption, particularly with multi-day patches.

 

  • Easy application with potential to reduce dosage interval.

  • Potential route for active substances where no other non-invasive delivery form is possible.

  • Controlled, balanced drug release with no peak concentrations for long effect and less side effects (e.g. nausea/vomiting).

  • Avoidance of first-pass metabolism for improved efficacy of active substances with low oral bioavailability and saving of expensive active substances.

  • Design options for individual positioning in the market.

  • Life cycle management of established products.

  • Especially suitable for patients with special needs (e.g. Parkinson’s disease).